Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from HilleVax

Kosmos Energy Posts Downbeat Q2 Results, Joins HilleVax And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were higher this morning, with the Dow futures gaining more than 200 points on Monday.

Benzinga · Aug 4, 2025

SVB Sees De-Risked Opportunity For This Newly Listed Norovirus Vaccine

SVB Leerink is initiating coverage of HilleVax Inc (NASDAQ:HLVX) shares with an Outperform rating and a $30 price target. The analyst believes the company’s potentially first-in-class infant norovirus vaccine HIL214 represents a uniquely de-risked opportunity. It estimates $625 million in risk-adjusted infant HIL214 sales in 2030E ($1 billion unadjusted). The outlook is supported by…

Benzinga · May 24, 2022

Benzinga's Top Ratings Upgrades, Downgrades For May 24, 2022

Upgrades

Benzinga · May 24, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

Executives Buy Around $85M Of 4 Stocks

Although crude oil futures traded higher on Wednesday, there were a few notable insider trades.

Benzinga · May 4, 2022

Preview: Hillevax, Inc Set To IPO Tomorrow

HilleVax, Inc (NASDAQ:HLVX) IPO will take place April, 29 on the NASDAQ exchange under the ticker HLVX. The company is offering shares at an expected price between $16.00 and $18.00 per share with an insider lock-up period of 180 days ending on October 26, 2022.

Benzinga · Apr 28, 2022

Coverage From

Benzinga

Organisations

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.